FVFilipe Luis Vasconcelos Visani

Filipe Luis Vasconcelos Visani

*This is an algorithmically generated author record based on publicly available information.

Filipe Luis Vasconcelos Visani has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Three-monthly gonadotropin-releasing hormone agonist for ovarian function suppression in premenopausal breast cancer: a systematic review and meta-analysis

    by Caio Dabbous de Liz, Pedro C. Abrahão Reis, Ellen R. Blanchard-Cavagis, Isabela C. Diniz, Heloísa Carneiro Brito, Filipe Luis Vasconcelos Visani

    Purpose: Ovarian function suppression (OFS) with gonadotropin-releasing hormone agonists (GnRHa) improves outcomes in premenopausal women with hormone receptor–positive (HR +) breast cancer (BC), most commonly using monthly administration. The potential equivalence of 3-monthly (3 M) versus monthly (1 M) schedules has been suggested but remains uncertain. Methods: We performed a systematic review and meta-analysis of interventional studies comparing 3 M and 1 M GnRHa regimens in premenopausal women with HR + BC receiving endocrine therapy. Outcomes included ovarian escape (OE), mean estradiol (E2) levels, disease-free survival (DFS), progression-free survival (PFS), and adverse events. Subgroup analyses were performed by estradiol assay type, and a sensitivity analysis restricted to RCTs. Results: Fifteen studies comprising 4,324 patients were included, of whom 2,098 (48%) received a 3 M regimen. The pooled OE was 10% and showed no significant difference between schedules (RR 0.86; 95% CI 0.60–1.22; p = 0.39). Ultrasensitive assays yielded higher OE detection (31%) without inter-regimen differences (RR 0.90; 95% CI 0.38–2.14). Mean E2 concentrations at 12 weeks were similar (MD 1.36 pg/mL; 95% CI –3.66 to 6.38), with consistent findings in RCT-only analyses (MD –1.77 pg/mL; 95% CI –5.71 to 2.17). DFS (RR 1.02; 95% CI 0.67–1.56) and PFS (RR 0.86; 95% CI 0.72–1.04) were also comparable. No clinically relevant differences were observed in reported safety outcomes. Conclusion: 3 M GnRHa achieved OFS efficacy comparable to 1 M regimens, with no meaningful differences in survival or safety. The findings support 3 M GnRHa as a valid and practical alternative for OFS in appropriately selected premenopausal women with HR + BC.


  • Increased detection of NRG1 fusions in non-squamous non–small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort

    by Breno Jeha Araújo, Filipe Visani, Rafael Duarte Paes, Christopher Lucas Negrete, Nathalia Pellegrini Correa, Fernanda Christtanini Koyama, Jéssica Vieira de Assis, Luciana Guedes de Almeida Valverde, Carolina de Bustamante Fernandes, Clarissa Mathias, et al.